AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16490395 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance-strength training regime for the cervical flexor muscles
Number of subjects: 58
Study 16490395 — intervention group
Group type: COMPARATOR
Intervention: Referent exercise intervention involving low load retraining of the cranio-cervical flexor muscles
Number of subjects: 58
Study 12623165 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide (10 microg/ml)
Number of subjects: 0
Study 12623165 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide (5-10 microg/ml)
Number of subjects: 0
Study 12623165 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide
Number of subjects: 0
Study 10688717 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% 4-hydroxyanisole (Mequinol) and 0.01% tretinoin solution (Solagé)
Number of subjects: 0
Study 10688717 — intervention group
Group type: COMPARATOR
Intervention: 0.01% tretinoin
Number of subjects: 0
Study 10688717 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study 9611297 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose-containing formula (Ninho 10%)
Number of subjects: 40
Study 9611297 — intervention group
Group type: COMPARATOR
Intervention: Lactose-free formula (Portagen)
Number of subjects: 40
Study 8456784 — intervention group
Group type: EXPERIMENTAL
Intervention: Debonding with orthodontic pliers and enamel clean-up with finishing burs and polishing disks (group 1)
Number of subjects: 30
Study 8456784 — intervention group
Group type: EXPERIMENTAL
Intervention: Debonding with orthodontic pliers and ultrasonic clean-up of the enamel surface (group 2)
Number of subjects: 30
Study 8456784 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic debonding enamel clean-up (group 3)
Number of subjects: 30
Study 3941214 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit weight training (substituted for volleyball)
Number of subjects: 40
Study 3941214 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular exercise: walk/jog and volleyball)
Number of subjects: 40
Study 3941214 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit weight training
Number of subjects: 40
Study 3941214 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular exercise)
Number of subjects: 40
Study 29368537 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide (TAF) regimen (elvitegravir, cobicistat, emtricitabine, TAF)
Number of subjects: 1436
Study 29368537 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate (TDF) regimen
Number of subjects: 1436
Study 29368537 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide (TAF) regimen
Number of subjects: 1436
Study 24814438 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwife assisted ultrasound guided embryo transfer (ET)
Number of subjects: 553
Study 24814438 — intervention group
Group type: COMPARATOR
Intervention: Doctor assisted ultrasound guided embryo transfer (ET)
Number of subjects: 553
Study 22840917 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin 2 g
Number of subjects: 22
Study 22840917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 20528801 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA supplementation
Number of subjects: 9
Study 20528801 — intervention group
Group type: COMPARATOR
Intervention: Flavoured water (control)
Number of subjects: 9
Study 20528801 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 9
Study 20528801 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA supplementation and resistance exercise
Number of subjects: 9
Study 18538913 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium silicate paste based on Portland cement (DSC)
Number of subjects: 4
Study 18538913 — intervention group
Group type: EXPERIMENTAL
Intervention: D/Sense Crystal (oxalate-based product)
Number of subjects: 4
Study 18538913 — intervention group
Group type: EXPERIMENTAL
Intervention: By Sealant (oxalate-based product)
Number of subjects: 4
Study 18538913 — intervention group
Group type: COMPARATOR
Intervention: GC Tooth Mousse (commercial re-mineralizing treatment)
Number of subjects: 4
Study 18538913 — intervention group
Group type: COMPARATOR
Intervention: Dentosan S (commercial toothpaste)
Number of subjects: 4
Study 16612708 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin injections (10 pmol/kg bw)
Number of subjects: 16
Study 16612708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 10704629 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A
Number of subjects: 0
Study 10704629 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 0
Study 10704629 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 10704629 — intervention group
Group type: EXPERIMENTAL
Intervention: All subjects
Number of subjects: 0
Study 10704629 — intervention group
Group type: EXPERIMENTAL
Intervention: FD patients
Number of subjects: 0
Study 9087480 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir, 7 mg/kg of body weight twice a day for 10 days
Number of subjects: 394
Study 9087480 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin, 10 mg/kg four times a day for 10 days
Number of subjects: 394
Study 8384645 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (5 ng/kg per min) infusion for 60 minutes
Number of subjects: 22
Study 8384645 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalaprilat (1 mg intravenously) administration
Number of subjects: 22
Study 8384645 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control infusion
Number of subjects: 22
Study 8384645 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control administration
Number of subjects: 22
Study 3739804 — intervention group
Group type: EXPERIMENTAL
Intervention: Response-contingent tone and puff
Number of subjects: 3
Study 3739804 — intervention group
Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 3
Study 3739804 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 3
Study 31585546 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall neonatal sepsis
Number of subjects: 504
Study 31585546 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-onset sepsis
Number of subjects: 504
Study 31585546 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-onset sepsis
Number of subjects: 504
Study 28399799 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg/kg (Group S)
Number of subjects: 56
Study 28399799 — intervention group
Group type: COMPARATOR
Intervention: Sugammadex 2 mg/kg with neostigmine 50 μg/kg (Group NS)
Number of subjects: 56
Study 26113439 — intervention group
Group type: EXPERIMENTAL
Intervention: ITF enriched breads (12% fructooligosaccharides and 12% inulin)
Number of subjects: 11
Study 23073720 — intervention group
Group type: EXPERIMENTAL
Intervention: Internally driven blink (participants were cued to blink their eyes)
Number of subjects: 0
Study 23073720 — intervention group
Group type: COMPARATOR
Intervention: Externally driven blink (offsetting and then onsetting the preview)
Number of subjects: 0
Study 21907536 — intervention group
Group type: EXPERIMENTAL
Intervention: Microincision hydrophilic intraocular lens (Idea 613 XC)
Number of subjects: 35
Study 21907536 — intervention group
Group type: COMPARATOR
Intervention: Standard hydrophobic open-loop acrylic IOL (Acrysof SA60AT)
Number of subjects: 35
Study 19165436 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Conservative Treatment (SCT)
Number of subjects: 111
Study 19165436 — intervention group
Group type: EXPERIMENTAL
Intervention: SCT and tendon and nerve gliding exercises
Number of subjects: 111
Study 19165436 — intervention group
Group type: COMPARATOR
Intervention: Tendon and nerve gliding exercises only
Number of subjects: 111
Study 16442888 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 63795
Study 16442888 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 63795
Study 16442888 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 63795
Study 16442888 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin, Simvastatin, Atorvastatin
Number of subjects: 63795
Study 15534165 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluviral S/F (Shire Biologics)
Number of subjects: 146
Study 15534165 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaxigrip (Aventis Pasteur)
Number of subjects: 146
Study 15534165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 11309019 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 49
Study 11309019 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 49
Study 11309019 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane and Halothane
Number of subjects: 49
Study 9232135 — intervention group
Group type: COMPARATOR
Intervention: Low intracuff pressure (30 mmHg)
Number of subjects: 70
Study 9232135 — intervention group
Group type: EXPERIMENTAL
Intervention: High intracuff pressure (180 mmHg)
Number of subjects: 70
Study 8489326 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine sulfate (average dose, 60 mg/d)
Number of subjects: 108
Study 8489326 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (average dose, 4 mg/d)
Number of subjects: 108
Study 8489326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 3031150 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone for group A
Number of subjects: 66
Study 3031150 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticotropin (ACTH) for group B
Number of subjects: 66
Study 3031150 — intervention group
Group type: COMPARATOR
Intervention: Prolonging therapy beyond 10 days by switching to the alternate corticoid drug
Number of subjects: 66
Study 3031150 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial therapy period
Number of subjects: 66
Study 3031150 — intervention group
Group type: COMPARATOR
Intervention: Continuing therapy beyond initial treatment
Number of subjects: 66
Study 29558423 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle modification programme (ILMP)
Number of subjects: 294
Study 29558423 — intervention group
Group type: EXPERIMENTAL
Intervention: GA + Metformin (GA + Met)
Number of subjects: 294
Study 29558423 — intervention group
Group type: COMPARATOR
Intervention: General advice (GA)
Number of subjects: 294
Study 25864773 — intervention group
Group type: EXPERIMENTAL
Intervention: DBT-informed skills training
Number of subjects: 41
Study 25864773 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 41
Study 24841548 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 835
Study 22124612 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental gingivitis (E-I test quadrants) induced by oral hygiene abstention for 21 days
Number of subjects: 37
Study 22124612 — intervention group
Group type: COMPARATOR
Intervention: Control quadrant with routine oral hygiene (E-I control quadrants)
Number of subjects: 37
Study 22124612 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental gingivitis (E-I test quadrants)
Number of subjects: 37
Study 22124612 — intervention group
Group type: COMPARATOR
Intervention: N-O gingivitis
Number of subjects: 37
Study 23057264 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen at 4L/min
Number of subjects: 70
Study 23057264 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplemental oxygen)
Number of subjects: 70
Study 18568324 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenfu Injection (SFI) 1.5 mL/kg administered into CPB priming fluid and pumped via CPB after aorta unclamping
Number of subjects: 40
Study 18568324 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenfu Injection (SFI) 1.5 mL/kg
Number of subjects: 40
Study 18568324 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SFI)
Number of subjects: 40
Study 15768198 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous baroreflex sensitivity (BRS) in ESRD patients
Number of subjects: 46
Study 15768198 — intervention group
Group type: COMPARATOR
Intervention: Temporal QT variability index (QTVI) in ESRD patients
Number of subjects: 46
Study 15768198 — intervention group
Group type: COMPARATOR
Intervention: Within-subject reproducibility of BRS measurements
Number of subjects: 46
Study 15768198 — intervention group
Group type: COMPARATOR
Intervention: Within-subject reproducibility of QTVI measurements
Number of subjects: 46
Study 15768198 — intervention group
Group type: COMPARATOR
Intervention: Coefficient of variation (CV) of within-subject reproducibility of BRS
Number of subjects: 46
Study 15768198 — intervention group
Group type: COMPARATOR
Intervention: Coefficient of variation (CV) of within-subject reproducibility of QTVI
Number of subjects: 46
Study 15768198 — intervention group
Group type: COMPARATOR
Intervention: Concordance correlation coefficients of within-subject variability of BRS and QTVI
Number of subjects: 46
Study 15768198 — intervention group
Group type: COMPARATOR
Intervention: CV of intra- and inter-examiner reproducibility of BRS and QTVI measurements
Number of subjects: 46
Study 12453707 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention (SI)
Number of subjects: 5887
Study 12453707 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 5887
Study 10360371 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisofylline (3 mg/kg every 6 h i.v.)
Number of subjects: 70
Study 10360371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 7618448 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous MgS04 therapy
Number of subjects: 0
Study 1786587 — intervention group
Group type: EXPERIMENTAL
Intervention: Olbetam (250 mg 3 x per day for 3 months)
Number of subjects: 24
Study 1786587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 7222718 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal (500 to 1000 mg per day)
Number of subjects: 16
Study 7222718 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid
Number of subjects: 16
Study 31351488 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose bio-optimized Curcuma longa extract (BCL)
Number of subjects: 150
Study 31351488 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose bio-optimized Curcuma longa extract (BCL)
Number of subjects: 150
Study 31351488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 31351488 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 150
Study 30195629 — intervention group
Group type: EXPERIMENTAL
Intervention: Coconut water
Number of subjects: 17
Study 30195629 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat sandwich
Number of subjects: 17
Study 26901576 — intervention group
Group type: EXPERIMENTAL
Intervention: PedaTyph™ vaccine (2 doses at 6 weeks interval)
Number of subjects: 1765
Study 26901576 — intervention group
Group type: COMPARATOR
Intervention: Control group (vaccines as per national guidelines)
Number of subjects: 1765
Study 26901576 — intervention group
Group type: EXPERIMENTAL
Intervention: PedaTyph™ vaccine
Number of subjects: 1765
Study 24986785 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana use
Number of subjects: 563
Study 22241898 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (anthracycline-based)
Number of subjects: 823
Study 22241898 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy (control group)
Number of subjects: 823
Study 22241898 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuclear p27 expression
Number of subjects: 823
Study 21180797 — intervention group
Group type: EXPERIMENTAL
Intervention: Gray mineral trioxide aggregate (MTA)
Number of subjects: 80
Study 21180797 — intervention group
Group type: COMPARATOR
Intervention: Silver amalgam without zinc (Am)
Number of subjects: 80
Study 17392721 — intervention group
Group type: EXPERIMENTAL
Intervention: Laropiprant 30, 100, and 300 mg coadministered with extended-release niacin
Number of subjects: 0
Study 17392721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15911904 — intervention group
Group type: EXPERIMENTAL
Intervention: Written disclosure condition
Number of subjects: 94
Study 15911904 — intervention group
Group type: COMPARATOR
Intervention: Control writing condition
Number of subjects: 94
Study 11919330 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mL 33% oral glucose given 2 min before the heel prick
Number of subjects: 120
Study 11919330 — intervention group
Group type: EXPERIMENTAL
Intervention: sucking
Number of subjects: 120
Study 11919330 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mL 33% oral glucose plus sucking
Number of subjects: 120
Study 11919330 — intervention group
Group type: EXPERIMENTAL
Intervention: multisensory stimulation including 1 mL 33% oral glucose
Number of subjects: 120
Study 11919330 — intervention group
Group type: EXPERIMENTAL
Intervention: multisensory stimulation without oral glucose
Number of subjects: 120
Study 11919330 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 120
Study 10067815 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication followed by daily dietary supplementation with antioxidant micronutrients
Number of subjects: 863
Study 7564362 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (5 mg ramipril and 6 mg piretanide)
Number of subjects: 611
Study 7564362 — intervention group
Group type: COMPARATOR
Intervention: Piretanide monotherapy
Number of subjects: 611
Study 7564362 — intervention group
Group type: COMPARATOR
Intervention: Ramipril monotherapy
Number of subjects: 611
Study 7564362 — intervention group
Group type: COMPARATOR
Intervention: Piretanide therapy
Number of subjects: 611
Study 7564362 — intervention group
Group type: COMPARATOR
Intervention: Combined therapy
Number of subjects: 611
Study 2188796 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 1000 mg twice daily (or 2000 mg once daily) for 10 to 15 days
Number of subjects: 55
Study 2188796 — intervention group
Group type: COMPARATOR
Intervention: Cefadroxil 1000 mg twice daily for 10 to 15 days
Number of subjects: 55
Study 6969559 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone, 30 mg/kg intravenously every 6 hours for four doses
Number of subjects: 42
Study 6969559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 29956019 — intervention group
Group type: EXPERIMENTAL
Intervention: WBV + RE
Number of subjects: 9
Study 29956019 — intervention group
Group type: COMPARATOR
Intervention: RE
Number of subjects: 9
Study 28596274 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate supplementation (70 ml, 0.4 g nitrate)
Number of subjects: 6
Study 28596274 — intervention group
Group type: COMPARATOR
Intervention: Nitrate-depleted (70 ml, 0 g nitrate)
Number of subjects: 6
Study 25901481 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxy 20 mg
Number of subjects: 39
Study 25901481 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxy 10 mg
Number of subjects: 39
Study 25901481 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxy (both doses)
Number of subjects: 39
Study 23843053 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training Group
Number of subjects: 96
Study 23843053 — intervention group
Group type: COMPARATOR
Intervention: Aerobic Exercise Group
Number of subjects: 96
Study 21245884 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary α‐tocopherol
Number of subjects: 25005
Study 21245884 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary β‐tocopherol
Number of subjects: 25005
Study 21245884 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary β‐tocotrienol
Number of subjects: 25005
Study 18852682 — intervention group
Group type: EXPERIMENTAL
Intervention: Parallel texture orientations
Number of subjects: 0
Study 18852682 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthogonal texture orientations
Number of subjects: 0
Study 17568798 — intervention group
Group type: EXPERIMENTAL
Intervention: Different types of UVB radiation
Number of subjects: 0
Study 15547060 — intervention group
Group type: EXPERIMENTAL
Intervention: Community based exercise programme
Number of subjects: 6416
Study 15547060 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 6416
Study 15766363 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic antibiotics (250 mg metronidazole and 375 mg amoxicillin three times a day for 7 days)
Number of subjects: 16
Study 15766363 — intervention group
Group type: COMPARATOR
Intervention: Enamel matrix derivative (EMD)
Number of subjects: 16
Study 15766363 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for systemic antibiotics)
Number of subjects: 16
Study 10599953 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg 3 times daily)
Number of subjects: 27
Study 10599953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 8735994 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked practice schedule
Number of subjects: 83
Study 8735994 — intervention group
Group type: COMPARATOR
Intervention: Alternating practice schedule
Number of subjects: 83
Study 1759491 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms PTxd
Number of subjects: 101
Study 1759491 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms PTxd
Number of subjects: 101
Study 1759491 — intervention group
Group type: COMPARATOR
Intervention: DTP
Number of subjects: 101
Study 6750068 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 20
Study 6750068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31975502 — intervention group
Group type: COMPARATOR
Intervention: Topical serum containing vitamin C (20% w/w), vitamin E, and raspberry leaf cell culture extract applied on one side of the face for 2 months.
Number of subjects: 50
Study 31975502 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical serum containing vitamin C, vitamin E, and raspberry leaf cell culture extract
Number of subjects: 50
Study 30100336 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol 1000 mg
Number of subjects: 200
Study 30100336 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dexketoprofen 50 mg
Number of subjects: 200